FDA’s groundbreaking handheld counterfeit detection device (CD-3) has been awarded a patent, according to a just-issued report by Securing Industry. The question I have is why this process took so long. This amazing device is relatively inexpensive and highly portable. It’s also extremely versatile and effective. How many devices that fit these criteria have the potential to field-test product as well as packaging for signs of counterfeiting and diversion? Few, if any, I suspect. I was one of the earliest proponents of this device within FDA and worked closely with its creators at the Forensic Chemistry Center to develop specialized training for FDA’s criminal investigative unit. Unfortunately, the timing was not right and our efforts largely fizzled. But maybe CD-3’s time has finally come. If given the chance to show its stuff to a wide audience, I’m convinced it will not disappoint (see my previous CD-3 posts here, here, and here).
- DECEPTIVE, UNETHICAL, AND POTENTIALLY CRIMINAL SHORTAGE DRUG DIVERSION SCHEMES CONTINUE TO THREATEN PATIENTS AND OUR HEALTH CARE SYSTEM July 13, 2018
- FDA’S LATEST STATEMENT ON DRUG SHORTAGES SIDESTEPS THE ROLE OF DIVERSION-AGAIN June 1, 2018
- STOLEN OCTAGAM COULD SIGNAL A NEW TREND FOR PHARMA CARGO THIEVES May 15, 2018
- FDA NEEDS TO ADOPT A LAW ENFORCEMENT SOLUTION TO THE TAINTED DIETARY SUPPLEMENT PROBLEM March 29, 2018
- FDA’S INTERNATIONAL MAIL FACILITY STRATEGY UNDERWHELMS March 23, 2018
- FDA’S OCTOBER 2017 COUNTERFEIT HARVONI NOTICE UNCOVERED February 7, 2018